Literature DB >> 8949981

Inhibitors of angiogenesis in a clinical perspective.

E E Voest1.   

Abstract

Inhibition of angiogenesis or preventing the outgrowth of new blood vessels towards a tumor is one of the most promising areas of anticancer drug development. Several angiogenesis inhibitors are now on the verge of being tested in clinical trials. This review discusses possible applications of inhibitors of angiogenesis and whether the current methodologies for testing novel anticancer drugs are appropriate to evaluate the efficacy of inhibitors of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8949981     DOI: 10.1097/00001813-199609000-00001

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy.

Authors:  C J Dimitroff; W Klohs; A Sharma; P Pera; D Driscoll; J Veith; R Steinkampf; M Schroeder; S Klutchko; A Sumlin; B Henderson; T J Dougherty; R J Bernacki
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Comprehensive Proteomic Profiling of Aqueous Humor Proteins in Proliferative Diabetic Retinopathy.

Authors:  Hu Xiao; Wen Xin; Li Mei Sun; Song Shan Li; Ting Zhang; Xiao Yan Ding
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.